Lunaphore Technologies SA, a Swiss life-sciences company developing innovative next generation equipment for cancer research and tissue diagnostics, announces the second closing of its Series C round totaling €23.7 million.
The €1.9 M Series C2 financing was provided by the Swiss Entrepreneurs Fund, who invested a total of €4.9M in the company. The fund is linked to the Swiss Entrepreneurs Foundation, whose main focus is to invest in Swiss start-ups and SMEs in the growth phase (internationalization) with the goal of bridging the financing gap in Swiss innovation.
Didier Denat, Member of the Decision Committee for direct investments of the Swiss Entrepreneurs Fund and Head of Corporate Banking at Credit Suisse (Switzerland) Ltd. said: “With its outstanding management team and technological USPs, Lunaphore is able to show significant market traction, combined with a high degree of customer satisfaction.
We are fully convinced in both the business model and strategy of Lunaphore and we are happy to contribute in taking the company to the next level.” The proceeds of the overall €23.7 Series C closing, with the first closing announced on February 6, 2020 and led by the Japanese strategic investor PHC Holdings Corporation (PHCHD), will be dedicated to market and product expansion, including a US market entry, the ramp up of activities in Europe and the development of next generation of instruments. “We are very happy to add the Swiss Entrepreneurs Fund, which focuses on highgrowth companies with global ambitions, to our investors’ base. Together with the strategic investment from PHCHD that we recently closed, Lunaphore is now backed by very strong institutions to achieve its vision.”
Show Comments